DURECT Corporation (DRRX)

0,9433 -0,0237 (-2,45%) In data: 09:57AM EDT. Mercato aperto.

DURECT Corporation

10240 Bubb Road
Cupertino, CA 95014-4166
United States
408 777 1417
https://www.durect.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 58

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. James E. Brown D.V.M.	Co-Founder, CEO, President & Director	633,46k	N/D	1957
Mr. Timothy M. Papp M.B.A.	CFO & Secretary	427,62k	N/D	1976
Dr. Norman L. Sussman M.D.	Chief Medical Officer	471,71k	N/D	1953
Ms. Judy R. Joice	Senior Vice President of Operations & Corporate Quality Assurance	451,82k	N/D	1957
Dr. WeiQi Lin M.D., Ph.D.	Executive VP of Research & Development and Principal Scientist	N/D	N/D	N/D
Mr. Keith L. Lui M.B.A.	Senior Vice President of Business Development, Commercial & Medical Affairs	N/D	N/D	N/D
Ms. Jian Li M.B.A.	Senior VP of Finance, Corporate Controller & Secretary	297,08k	16,41k	1970
Dr. Su Il Yum Ph.D.	Executive Officer	331,74k	62,44k	1939

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Governance aziendale

L'ISS Governance QualityScore di DURECT Corporation al 29 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 2; diritti degli azionisti: 7; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.